We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

137 hedge funds and large institutions have $1.41B invested in Lexicon Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 33

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

1% more funds holding

Funds holding: 135 → 137 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.4% less ownership

Funds ownership: 109.14% → 108.74% (-0.4%)

25% less capital invested

Capital invested by funds: $1.89B → $1.41B (-$478M)

88% less call options, than puts

Call options by funds: $1.77M | Put options by funds: $14.2M

Holders
137
Holders Change
+2
Holders Change %
+1.48%
% of All Funds
3.42%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
44
Reduced
33
Closed
20
Calls
$1.77M
Puts
$14.2M
Net Calls
-$12.4M
Net Calls Change
-$26.6M

Top Buyers

1
KCM
Kornitzer Capital Management
Kansas
+$11.3M
2
Bank of America
Bank of America
North Carolina
+$6.06M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$5.18M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$4.15M
5
PA
Pinnacle Associates
New York
+$2.69M

Top Sellers

1
Norges Bank
Norges Bank
Norway
-$12.5M
2
KCM
Kingdon Capital Management
New York
-$7.96M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$5.61M
4
Millennium Management
Millennium Management
New York
-$4.56M
5
CCI
Columbus Circle Investors
-$3.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
101
Virtu Financial
New York
$147K +$177K +11,993 New
WP
102
WMS Partners
Maryland
$138K +$17.7K +1,200 +12%
NIT
103
NumerixS Investment Technologies
British Columbia, Canada
$123K -$90.1K -6,100 -38%
Canada Life
104
Canada Life
Manitoba, Canada
$97K – – –
SC
105
Sculptor Capital
New York
$92K – – –
BNP Paribas Financial Markets
106
BNP Paribas Financial Markets
France
$63.1K -$4.59K -311 -6%
First Manhattan
107
First Manhattan
New York
$61K – – –
Royal Bank of Canada
108
Royal Bank of Canada
Ontario, Canada
$58K +$64.9K +4,398 +1,232%
AIP
109
Ameritas Investment Partners
Nebraska
$57K – – –
PWM
110
Perigon Wealth Management
California
$43K +$51.5K +3,489 New
TRCT
111
Tower Research Capital (TRC)
New York
$41K +$49.4K +3,343 New
ClearBridge Investments
112
ClearBridge Investments
New York
$31K +$4.5K +305 +14%
IA
113
IFP Advisors
Florida
$26K -$812 -55 -3%
Envestnet Asset Management
114
Envestnet Asset Management
Illinois
$26K +$1.62K +110 +5%
CLOS
115
Compagnie Lombard Odier SCmA
Switzerland
$22K – – –
Victory Capital Management
116
Victory Capital Management
Texas
$19K – – –
RE
117
RBC Europe
United Kingdom
$18.4K +$22.2K +1,500 New
Zurich Cantonal Bank
118
Zurich Cantonal Bank
Switzerland
$16K – – –
GXMC
119
Global X Management Company
New York
$15K +$2.56K +173 +17%
LTFS
120
Ladenburg Thalmann Financial Services
Florida
$13K -$27K -1,828 -63%
LWM
121
Lenox Wealth Management
Ohio
$12K – – –
Bank of Montreal
122
Bank of Montreal
Ontario, Canada
$11K -$856K -57,933 -99%
KF
123
Krilogy Financial
Missouri
$10K – – –
Nisa Investment Advisors
124
Nisa Investment Advisors
Missouri
$8K – – –
AG
125
Advisor Group
Arizona
$8K +$2.13K +144 +27%
3 4
5
6 7

LXRX Hedge Fund Activity: Q3 2017 in Review

137 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2017, worth a combined $1.41B — down 25% from $1.89B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LXRX positions and 20 closed out — a net gain of 3 holders — while 44 added to existing stakes and 33 trimmed.

The largest buyer was Kornitzer Capital Management, opening a new position worth an estimated $11.3M. The largest seller was Norges Bank, cutting an estimated $12.5M.

  • 137 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2017, up from 135 in Q2 2017.
  • Funds reported $1.41B of Lexicon Pharmaceuticals stock for Q3 2017, down 25% quarter-over-quarter.
  • 23 funds opened new Lexicon Pharmaceuticals positions in Q3 2017 and 20 closed out, a net change of +3 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q3 2017 was Kornitzer Capital Management, an estimated $11.3M added.
  • The largest Lexicon Pharmaceuticals seller in Q3 2017 was Norges Bank, an estimated $12.5M sold.

Based on aggregated 13F filings for Q3 2017.